Seidman, Andrew

Publications

Sort by

Co-Author Network

selected publications

Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer. Journal of neuro-oncology. 2020 Academic Article GET IT
Times cited: 32
"A Tool, Not a Crutch": Patient Perspectives About IBM Watson for Oncology Trained by Memorial Sloan Kettering. Journal of oncology practice. 2019 Academic Article GET IT
Phase 2 Study of Dose-Dense Doxorubicin and Cyclophosphamide Followed by Eribulin Mesylate With or Without Prophylactic Growth Factor for Adjuvant Treatment of Early-Stage Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer. Clinical breast cancer. 2018 Academic Article GET IT
Times cited: 8
Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer. Clinical breast cancer. 2018 Academic Article GET IT
Times cited: 29
An Important Step Forward for Biosimilars in Cancer Treatment. JAMA oncology. 2017 Academic Article GET IT
Times cited: 3
Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk. Breast cancer research and treatment. 2016 Academic Article GET IT
Times cited: 198
Characteristics and Outcomes of Patients With Breast Cancer With Leptomeningeal Metastasis. Clinical breast cancer. 2016 Academic Article GET IT
Times cited: 72
When to Combine Endocrine Therapy With a New Agent for Hormone Receptor-Positive Metastatic Breast Cancer in Postmenopausal Women. Oncology (Williston Park, N.Y.). 2016 Academic Article GET IT
Times cited: 1
Outcomes and prognostic factors in women with 1 to 3 breast cancer brain metastases treated with definitive stereotactic radiosurgery. International journal of radiation oncology, biology, physics. 2014 Academic Article GET IT
Times cited: 26
Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study. Neuro-oncology. 2014 Academic Article GET IT
Times cited: 131
A pooled analysis of gemcitabine plus docetaxel versus capecitabine plus docetaxel in metastatic breast cancer. The oncologist. 2014 Academic Article GET IT
Times cited: 11
Phase II trial of patupilone in patients with brain metastases from breast cancer. Neuro-oncology. 2014 Academic Article GET IT
Times cited: 21
Randomized phase II trial of weekly vs. every 2 weeks vs. every 3 weeks nanoparticle albumin-bound paclitaxel with bevacizumab as first-line chemotherapy for metastatic breast cancer. Clinical breast cancer. 2013 Academic Article GET IT
Times cited: 30
The search for an elusive uniform strategy for a heterogeneous disease: lesson learned?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Editorial Article GET IT
Times cited: 3
Electrophysiological features of taxane-induced polyneuropathy in patients with breast cancer. Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society. 2013 Academic Article GET IT
Times cited: 24
Hepatic arterial infusion and systemic chemotherapy for breast cancer liver metastases. The breast journal. 2012 Academic Article GET IT
Times cited: 9
Limited overall survival in patients with brain metastases from triple negative breast cancer. The breast journal. 2012 Academic Article GET IT
Times cited: 26
Adjuvant therapy in stage I carcinoma of the breast: the influence of multigene analyses and molecular phenotyping. The breast journal. 2012 Conference Paper GET IT
Times cited: 8
Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Academic Article GET IT
Times cited: 86
Current or recent pregnancy is associated with adverse pathologic features but not impaired survival in early breast cancer. Cancer. 2011 Academic Article GET IT
Times cited: 74
A phase II pilot trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group. Annals of oncology : official journal of the European Society for Medical Oncology. 2011 Academic Article GET IT
Times cited: 20
Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840. Annals of oncology : official journal of the European Society for Medical Oncology. 2011 Academic Article GET IT
Times cited: 45
How long is long enough?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Editorial Article GET IT
Times cited: 3
Breast carcinoma with brain metastases: clinical analysis and immunoprofile on tissue microarrays. Annals of oncology : official journal of the European Society for Medical Oncology. 2011 Academic Article GET IT
Times cited: 32
A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2011 Academic Article GET IT
Times cited: 49
A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 25
The need to examine metastatic tissue at the time of progression of breast cancer: is re-biopsy a necessity or a luxury?. Current oncology reports. 2011 Review GET IT
Times cited: 28
Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancer. Clinical breast cancer. 2010 Academic Article GET IT
Times cited: 5
Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2010 Academic Article GET IT
Times cited: 28
Clinical cancer advances 2010: annual report on progress against cancer from the American Society of Clinical Oncology. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Academic Article GET IT
Times cited: 54
Adjuvant taxanes: more to the story. Clinical breast cancer. 2010 Review GET IT
Times cited: 11
Brain metastases from breast cancer. Clinical advances in hematology & oncology : H&O. 2010 Article GET IT
Times cited: 2
Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer. Clinical breast cancer. 2010 Academic Article GET IT
Times cited: 77
A prospective evaluation of the durability of palliative interventions for patients with metastatic breast cancer. Cancer. 2010 Academic Article GET IT
Times cited: 7
Holding back the sea: the role for maintenance chemotherapy in metastatic breast cancer. Breast cancer research and treatment. 2010 Comment GET IT
Times cited: 6
A randomized phase 2 trial comparing 3-hour versus 96-hour infusion schedules of paclitaxel for the treatment of metastatic breast cancer. Cancer. 2010 Academic Article GET IT
Times cited: 19
Maitake beta-glucan promotes recovery of leukocytes and myeloid cell function in peripheral blood from paclitaxel hematotoxicity. Cancer immunology, immunotherapy : CII. 2010 Academic Article GET IT
Times cited: 15
Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 42
Evolving approaches to metastatic breast cancer previously treated with anthracyclines and taxanes. Clinical breast cancer. 2009 Review GET IT
Times cited: 21
A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients: immunological effects. Journal of cancer research and clinical oncology. 2009 Academic Article GET IT
Times cited: 153
A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 Academic Article GET IT
Times cited: 103
Beyond cytotoxic chemotherapy for the first-line treatment of HER2-negative, hormone-insensitive metastatic breast cancer: current status and future opportunities. Clinical breast cancer. 2008 Review GET IT
Times cited: 27
Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 30
Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 531
The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 51
Point: combination versus single-agent chemotherapy: the argument for sequential single agents. Journal of the National Comprehensive Cancer Network : JNCCN. 2007 Academic Article GET IT
Times cited: 6
Emerging targeted therapies for breast cancer. Hematology/oncology clinics of North America. 2007 Review GET IT
Times cited: 4
Increased dose density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Academic Article GET IT
Times cited: 9
Taxanes in breast cancer: an update. Current oncology reports. 2007 Review GET IT
Times cited: 39
Use of the Oncotype DX 21-gene assay to guide adjuvant decision making in early-stage breast cancer. Molecular diagnosis & therapy. 2007 Review GET IT
Times cited: 19
Adjuvant therapy with aromatase inhibitors for postmenopausal women with early breast cancer: evidence and ongoing controversy. Seminars in oncology. 2006 Review GET IT
Times cited: 19
Cardiac dysfunction associated with trastuzumab. Expert opinion on drug safety. 2006 Review GET IT
Times cited: 39
A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer. Clinical breast cancer. 2006 Academic Article GET IT
Times cited: 82
Systemic treatment of breast cancer. Two decades of progress. Oncology (Williston Park, N.Y.). 2006 Review GET IT
Times cited: 16
A prospective, longitudinal study of the functional status and quality of life of older patients with breast cancer receiving adjuvant chemotherapy. Journal of the American Geriatrics Society. 2006 Academic Article GET IT
Times cited: 78
Is trastuzumab active following conventional adjuvant chemotherapy in HER2-positive early breast cancer?. Nature clinical practice. Oncology. 2006 Academic Article GET IT
Times cited: 3
Current status of dose-dense chemotherapy for breast cancer. Cancer chemotherapy and pharmacology. 2005 Review GET IT
Times cited: 11
"Will weekly work"? Seems to be so... Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Editorial Article GET IT
Times cited: 26
A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane. Clinical breast cancer. 2005 Academic Article GET IT
Times cited: 54
Emerging targeted therapies for breast cancer. Oncology (Williston Park, N.Y.). 2005 Review GET IT
Times cited: 9
A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer. Breast cancer research and treatment. 2005 Academic Article GET IT
Times cited: 82
Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate. Annals of oncology : official journal of the European Society for Medical Oncology. 2005 Academic Article GET IT
Times cited: 112
Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer. Cancer investigation. 2005 Academic Article GET IT
Times cited: 38
Gemcitabine and docetaxel in metastatic breast cancer. Oncology (Williston Park, N.Y.). 2004 Review GET IT
Times cited: 10
Effect of cardiac dysfunction on treatment outcomes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer. Clinical breast cancer. 2004 Academic Article GET IT
Times cited: 33
New advances in taxane therapy: the next generation. Journal of the National Comprehensive Cancer Network : JNCCN. 2004 Academic Article GET IT
Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Academic Article GET IT
Times cited: 29
Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Academic Article GET IT
Times cited: 58
Cardiac effects of adjuvant therapy for early breast cancer. Seminars in oncology. 2003 Review GET IT
Times cited: 51
Introduction. Single-agent or combination chemotherapy in metastatic breast cancer. Oncology (Williston Park, N.Y.). 2003 Review GET IT
Times cited: 2
Dose-dense treatment prolongs disease-free survival of women with node positive breast cancer. Cancer treatment reviews. 2003 Academic Article GET IT
Monotherapy options in the management of metastatic breast cancer. Seminars in oncology. 2003 Review GET IT
Times cited: 37
Sequential single-agent chemotherapy for metastatic breast cancer: therapeutic nihilism or realism?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003 Editorial Article GET IT
Times cited: 27
Cardiac dysfunction in clinical trials of trastuzumab. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002 Letter GET IT
HER2 testing and correlation with efficacy of trastuzumab therapy. Oncology (Williston Park, N.Y.). 2002 Review GET IT
Times cited: 74
Prospective exploratory analysis of the association between tumor response, quality of life, and expenditures among patients receiving paclitaxel monotherapy for refractory metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002 Academic Article GET IT
Times cited: 25
Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002 Academic Article GET IT
Times cited: 73
Cardiac dysfunction in the trastuzumab clinical trials experience. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002 Academic Article GET IT
Times cited: 1287
Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel. Clinical cancer research : an official journal of the American Association for Cancer Research. 2002 Academic Article GET IT
Times cited: 81
An update on epidermal growth factor receptor inhibitors. Current oncology reports. 2002 Review GET IT
Times cited: 28
Combination versus sequential single-agent therapy in metastatic breast cancer. The oncologist. 2002 Review GET IT
Times cited: 157
Critical review of current treatment strategies for advanced hormone insensitive breast cancer. Cancer investigation. 2002 Review GET IT
Times cited: 8
Incorporating oral capecitabine into the treatment of breast cancer. Introduction. The oncologist. 2002 Academic Article GET IT
Times cited: 1
Single-agent capecitabine: a reference treatment for taxane-pretreated metastatic breast cancer?. The oncologist. 2002 Review GET IT
Times cited: 47
Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2001 Academic Article GET IT
Times cited: 29
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001 Academic Article GET IT
Times cited: 545
Oral gossypol in the treatment of patients with refractory metastatic breast cancer: a phase I/II clinical trial. Breast cancer research and treatment. 2001 Academic Article GET IT
Times cited: 193
Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001 Academic Article GET IT
Times cited: 78
Gemcitabine as single-agent therapy in the management of advanced breast cancer. Oncology (Williston Park, N.Y.). 2001 Review GET IT
Times cited: 29
Breast disease. Introduction. Breast disease. 2001 Academic Article GET IT
Pharmacologic insights into the future of trastuzumab. Annals of oncology : official journal of the European Society for Medical Oncology. 2001 Review GET IT
Times cited: 18
The evolving role of gemcitabine in the management of breast cancer. Oncology. 2001 Review GET IT
Times cited: 17
Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer. Seminars in oncology. 2000 Review GET IT
Times cited: 38
Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2000 Academic Article GET IT
Times cited: 680
An immunotherapeutic approach to treatment of breast cancer: focus on trastuzumab plus paclitaxel. Breast Cancer Medicine Service. Cancer chemotherapy and pharmacology. 2000 Review GET IT
Times cited: 8
Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Seminars in oncology. 1999 Academic Article GET IT
Times cited: 267
Single-agent paclitaxel in the treatment of breast cancer: phase I and II development. Seminars in oncology. 1999 Review GET IT
Times cited: 24
Update on the management of advanced breast cancer. Oncology (Williston Park, N.Y.). 1999 Review GET IT
Times cited: 38
5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: A phase II study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1999 Academic Article GET IT
Times cited: 50
Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 1999 Academic Article GET IT
Times cited: 11
Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1999 Academic Article GET IT
Times cited: 91
Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998 Review GET IT
Times cited: 394
Lack of increased cardiac toxicity with sequential doxorubicin and paclitaxel. Cancer investigation. 1998 Academic Article GET IT
Times cited: 10
One-hour paclitaxel via weekly infusion: dose-density with enhanced therapeutic index. Oncology (Williston Park, N.Y.). 1998 Academic Article GET IT
Times cited: 21
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998 Academic Article GET IT
Times cited: 392
Docetaxel: a new active agent in the therapy of metastatic breast cancer. Expert opinion on investigational drugs. 1997 Academic Article GET IT
Times cited: 21
Phase II study of semisynthetic paclitaxel in metastatic breast cancer. European journal of cancer (Oxford, England : 1990). 1997 Academic Article GET IT
Times cited: 14
Dose-dense therapy with paclitaxel via weekly 1-hour infusion: preliminary experience in the treatment of metastatic breast cancer. Seminars in oncology. 1997 Academic Article GET IT
Times cited: 18
Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing. Journal of neuro-oncology. 1997 Academic Article GET IT
Times cited: 158
Docetaxel and paclitaxel in breast cancer therapy: present status and future prospects. Seminars in oncology. 1997 Review GET IT
Times cited: 32
HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. Oncology (Williston Park, N.Y.). 1997 Review GET IT
Times cited: 149
Paclitaxel for breast cancer: the Memorial Sloan-Kettering Cancer Center experience. Oncology (Williston Park, N.Y.). 1997 Review GET IT
Times cited: 19
Motor neuropathy due to docetaxel and paclitaxel. Neurology. 1996 Academic Article GET IT
Times cited: 133
Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1996 Academic Article GET IT
Times cited: 154
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1996 Academic Article GET IT
Times cited: 1276
Chemotherapy for advanced breast cancer: a current perspective. Seminars in oncology. 1996 Review GET IT
Times cited: 25
Sequential adjuvant therapy: the Memorial Sloan-Kettering Cancer Center experience. Seminars in oncology. 1996 Academic Article GET IT
Times cited: 28
Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1996 Academic Article GET IT
Times cited: 148
Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes. Seminars in oncology. 1995 Academic Article GET IT
Times cited: 23
Memorial Sloan-Kettering Cancer Center experience with paclitaxel in the treatment of breast cancer. Seminars in oncology. 1995 Review GET IT
Times cited: 5
Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1995 Academic Article GET IT
Times cited: 209
Quality of life in phase II trials: a study of methodology and predictive value in patients with advanced breast cancer treated with paclitaxel plus granulocyte colony-stimulating factor. Journal of the National Cancer Institute. 1995 Academic Article GET IT
Times cited: 86
Memorial Sloan-Kettering Cancer Center experience with paclitaxel in the treatment of breast cancer: from advanced disease to adjuvant therapy. Seminars in oncology. 1995 Academic Article GET IT
Times cited: 25
Central nervous system progression of metastatic breast cancer in patients treated with paclitaxel. Cancer. 1995 Academic Article GET IT
Times cited: 106
Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1995 Academic Article GET IT
Times cited: 218
The emerging role of paclitaxel in breast cancer therapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 1995 Review GET IT
Times cited: 55
Flare on bone scintigraphy following Taxol chemotherapy for metastatic breast cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 1994 Academic Article GET IT
Times cited: 81
Taxol (paclitaxel) plus recombinant human granulocyte colony-stimulating factor in the treatment of metastatic breast cancer. Oncology. 1994 Academic Article GET IT
Times cited: 3
Photopsia during 3-hour paclitaxel administration at doses > or = 250 mg/m2. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1994 Letter GET IT
Times cited: 34
Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1994 Academic Article GET IT
Times cited: 141
Single-agent use of Taxol (paclitaxel) in breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 1994 Review GET IT
Times cited: 15
Taxol (paclitaxel): a novel anti-microtubule agent with remarkable anti-neoplastic activity. International journal of clinical & laboratory research. 1994 Review GET IT
Times cited: 86
Taxol and recombinant human granulocyte colony-stimulating factor, an active regimen as initial therapy for metastatic breast cancer. A preliminary report. Annals of the New York Academy of Sciences. 1993 Academic Article GET IT
Times cited: 2
Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1993 Academic Article GET IT
Times cited: 236
Preliminary experience with paclitaxel (Taxol) plus recombinant human granulocyte colony-stimulating factor in the treatment of breast cancer. Seminars in oncology. 1993 Academic Article GET IT
Times cited: 45
Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1993 Academic Article GET IT
Times cited: 100
Phase II trial of carboplatin and etoposide in metastatic breast cancer. Cancer. 1993 Academic Article GET IT
Times cited: 14
Immune-mediated thrombocytopenia secondary to suramin. 1993 GET IT
Times cited: 13
Taxol plus recombinant human granulocyte-colony stimulating factor as initial and as salvage chemotherapy for metastatic breast cancer: a preliminary report. Journal of the National Cancer Institute. Monographs. 1993 Academic Article GET IT
Times cited: 12
Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer. The Journal of urology. 1992 Academic Article GET IT
Times cited: 193
Continuous infusion gallium nitrate for patients with advanced refractory urothelial tract tumors. Cancer. 1991 Academic Article GET IT
Times cited: 89
The evolving role of chemotherapy for muscle infiltrating bladder cancer. Seminars in oncology. 1991 Review GET IT
Times cited: 19

more ...

less ...

Background

education and training

M.D., Medical College of Pennsylvania and Hahnemann University 1985
B.S., State University of New York at Binghamton 1981

Contact

full name

Andrew Seidman

VIVO Weill Cornell Medical College

Andrew Seidman Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

Phone

Publications

selected publications

Background

education and training

Contact

full name